Literature DB >> 8400082

Oxidative modification of low-density lipoproteins by mesangial cells.

W F Keane1, M P O'Donnell, B L Kasiske, Y Kim.   

Abstract

Because hypercholesterolemia and mesangial cell proliferation may be important in the pathogenesis of glomerulosclerosis, the effects of low-density lipoprotein (LDL) on human mesangial cell proliferation were evaluated. Native LDL (20 to 200 micrograms/mL) caused a dose-dependent increase in (3H)thymidine incorporation and increased mesangial cell numbers over 96 h. The mitogenic effect of LDL was partially blocked by the inhibition of cytochrome P-450, but not by the inhibition of cyclooxygenase or lipoxygenase pathways. Higher LDL concentrations (1,000 to 2,000 micrograms/mL) inhibited (3H)thymidine incorporation and reduced cell numbers, possibly as a result of the oxidative modification of LDL, indicated by an increase in thiobarbituric reactive substances. This peroxidation of LDL involved superoxide, because superoxide dismutase and butylated hydroxytoluene prevented it, whereas hydroxyl radical scavengers were without effect. Native LDL subjected to chemical oxidation by copper sulfate also inhibited mesangial cell proliferation. These results suggest that low concentrations of LDL may stimulate human mesangial cell proliferation, which may, in turn, cause the production of reactive oxygen molecules. Moreover, the oxidative modification of LDL may mediate the toxic effects of high LDL concentrations on human mesangial cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400082     DOI: 10.1681/ASN.V42187

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

Review 1.  HMG-CoA reductase inhibitors and the kidney.

Authors:  Vito M Campese; Bassel Hadaya; Josephine Chiu
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

2.  Immunological evidence for hypochlorite-modified proteins in human kidney.

Authors:  E Malle; C Woenckhaus; G Waeg; H Esterbauer; E F Gröne; H J Gröne
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 3.  Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Maciej Banach; Andrzej Więcek
Journal:  Int Urol Nephrol       Date:  2015-03-11       Impact factor: 2.370

4.  Low density lipoprotein enhances the cellular action of arginine vasopressin in rat glomerular mesangial cells in culture.

Authors:  S Ishikawa; M Kawasumi; K Okada; T Saito
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort.

Authors:  Taku Inoue; Kunitoshi Iseki; Chiho Iseki; Yusuke Ohya; Kozen Kinjo; Shuichi Takishita
Journal:  Clin Exp Nephrol       Date:  2009-05-15       Impact factor: 2.801

Review 6.  An update on 'progression promoters' in renal diseases.

Authors:  C O Alebiosu
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

7.  Low-grade inflammation, metabolic syndrome and the risk of chronic kidney disease: the 2005 Korean National Health and Nutrition Examination Survey.

Authors:  Hee-Taik Kang; Jong-Koo Kim; Jae-Yong Shim; Hye-Ree Lee; John A Linton; Yong-Jae Lee
Journal:  J Korean Med Sci       Date:  2012-05-26       Impact factor: 2.153

8.  Elevated atherogenic index and higher triglyceride increase risk of kidney function decline: a 7-year cohort study in Chinese adults.

Authors:  Fei Huang; Le Wang; Qian Zhang; Zhengce Wan; Liu Hu; Ranran Xu; Anying Cheng; Yongman Lv; Qingquan Liu
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

9.  Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in Korean adults.

Authors:  Ji-Young Kim; Hee-Taik Kang; Hye-Ree Lee; Yong-Jae Lee; Jae-Yong Shim
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.